Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) EBITDA (2016 - 2025)

Historic EBITDA for AtriCure (ATRC) over the last 17 years, with Q3 2025 value amounting to -$443000.0.

  • AtriCure's EBITDA rose 9403.85% to -$443000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.1 million, marking a year-over-year increase of 2394.12%. This contributed to the annual value of -$44.7 million for FY2024, which is 6367.29% down from last year.
  • AtriCure's EBITDA amounted to -$443000.0 in Q3 2025, which was up 9403.85% from -$5.2 million recorded in Q2 2025.
  • AtriCure's 5-year EBITDA high stood at $97.0 million for Q3 2021, and its period low was -$17.7 million during Q1 2022.
  • In the last 5 years, AtriCure's EBITDA had a median value of -$8.6 million in 2023 and averaged -$4.4 million.
  • Per our database at Business Quant, AtriCure's EBITDA skyrocketed by 212214.35% in 2021 and then plummeted by 18939.75% in 2023.
  • Quarter analysis of 5 years shows AtriCure's EBITDA stood at -$14.5 million in 2021, then skyrocketed by 79.48% to -$3.0 million in 2022, then plummeted by 189.4% to -$8.6 million in 2023, then plummeted by 91.39% to -$16.5 million in 2024, then surged by 97.31% to -$443000.0 in 2025.
  • Its last three reported values are -$443000.0 in Q3 2025, -$5.2 million for Q2 2025, and -$5.9 million during Q1 2025.